Article (Scientific journals)
Quality assurance for prospective EORTC radiation oncology trials: The challenges of advanced technology in a multicenter international setting
Weber, D. C.; Poortmans, P. M. P.; Hurkmans, C. W. et al.
2011In Radiotherapy and Oncology, 100 (1), p. 150-156
Peer Reviewed verified by ORBi
 

Files


Full Text
Weber et al. - 2011 - Quality assurance for prospective EORTC radiation oncology trials The challenges of advanced technology in a multicenter international setting. - Radiother Oncol.pdf
Publisher postprint (309.36 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Clinical trial; EORTC; Quality assurance; Radiation Oncology Group; Radiotherapy; Clinical Trials as Topic; Europe; Humans; Multicenter Studies as Topic; Neoplasms; Prospective Studies; Quality Assurance, Health Care; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated
Abstract :
[en] The European Organization for the Research and Treatment of Cancer (EORTC) is a pan-European structure charged with improving cancer treatment through the testing of new therapeutic strategies in phases I-III clinical studies. Properly conducted trials in radiation oncology are required to demonstrate superiority of a new treatment over the current standard. The Radiation Oncology Group (ROG) has initiated a complex quality assurance (QA) program to ensure safe and effective treatment delivery. Most modern trials are multicenter and multidisciplinary, further increasing the importance of early, strict and consistent QA in radiotherapy (RT). QART measures confirm whether a site possesses minimum staff and equipment for participation. Dummy runs, reviews of patient treatment plans and complex dosimetry checks verify the ability of an institution to comply with the protocol. Data required for evaluation are increasingly exchanged digitally, allowing detailed plan reconstruction, evaluation of target volume delineation and recalculation of dose-volume parameters for comparison against predefined standards. The five tiers of QA implemented in EORTC trials are reviewed, along with past, current and future QART initiatives. As substantial human and financial resources are increasingly invested in QART, the importance of cost-benefit analysis of QA and its impact on clinical outcome cannot be overstated. © 2011 Elsevier Ltd. All rights reserved.
Disciplines :
Radiology, nuclear medicine & imaging
Author, co-author :
Weber, D. C.;  Geneva University Hospital, Switzerland
Poortmans, P. M. P.;  Institute Verbeeten, Tilburg, Netherlands
Hurkmans, C. W.;  Catharina Hospital, Eindhoven, Netherlands
Aird, E.;  Mount Vernon Hospital, Northwood, United Kingdom
GULYBAN, Akos ;  Centre Hospitalier Universitaire de Liège - CHU > Radiothérapie
Fairchild, A.;  EORTC, 83 Ave. E Mounierlaan, Brussels 1200, Belgium
Language :
English
Title :
Quality assurance for prospective EORTC radiation oncology trials: The challenges of advanced technology in a multicenter international setting
Publication date :
2011
Journal title :
Radiotherapy and Oncology
ISSN :
0167-8140
eISSN :
1879-0887
Publisher :
Elsevier Scientific, Limerick, Ireland
Volume :
100
Issue :
1
Pages :
150-156
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 20 June 2013

Statistics


Number of views
59 (2 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
74
Scopus citations®
without self-citations
52
OpenCitations
 
71

Bibliography


Similar publications



Contact ORBi